Comparative Analysis of IMT-P8 and LDP12 Cell-Penetrating Peptides in Increasing Immunostimulatory Properties of HIV-1 Nef-MPER-V3 Antigen DOI
Seyed Mehdi Sadat,

Shekoufa Jahedian,

Sahar Sabaghzadeh

et al.

Protein and Peptide Letters, Journal Year: 2024, Volume and Issue: 31(10), P. 818 - 826

Published: Nov. 19, 2024

There have been great efforts in vaccine design against HIV-1 since 1981. Various approaches investigated, including optimized delivery systems and effective adjuvants to enhance the efficacy of selective antigen targets. In this study, we evaluated efficiency IMT-P8 LDP12 cell penetrating peptides eliciting immune responses Nef-MPER-V3 fusion protein as an candidate. Moreover, potency HP91 HSP27 was compared adjuvant female BALB/c mice through different regimens. For purpose, recombinant Nef-MPER-V3, IMT-P8-Nef-MPER-V3 LDP-Nef- MPER-V3 proteins were generated on a large scale. After immunization with regimens, secretion antibodies, cytokines granzyme B by ELISA. Our results demonstrated that immunized receiving linked exhibited significantly higher levels IgG other groups. The IMT-P8-Nef- Hp91 group showed highest level humoral response, which stronger than formulation using same (LDP-Nef-MPER-V3). Additionally, combination either or Hsp27 resulted robust induction IFN-γ LDP-Nef-MPER-V3 group. Furthermore, cytotoxic T lymphocyte (CTL) activation proliferation assays indicated served more CPP, particularly when used conjunction adjuvant. Altogether, data formulations responses. This has high induce both immunity arms, specifically incorporated IMT-P8, priority LDP12. greater cellular HSP27. These findings suggest potential superior system for enhancing development.

Language: Английский

Nanoparticle-mediated enhancement of DNA Vaccines: Revolutionizing immunization strategies DOI

Pegah Yaraghi,

Abbas Kheyri,

Narges Mikaeili

et al.

International Journal of Biological Macromolecules, Journal Year: 2025, Volume and Issue: 302, P. 140558 - 140558

Published: Feb. 1, 2025

Language: Английский

Citations

0
Identification of immunogenic HLA-A*02:01 epitopes associated with HCC for immunotherapy development DOI Creative Commons
Anthony Maino, Ekaterina Bourova-Flin, Thomas Decaens

et al.

Hepatology Communications, Journal Year: 2025, Volume and Issue: 9(3)

Published: Feb. 26, 2025

Background: HCC is the most common form of primary liver cancer, and despite recent advances in cancer treatment, it remains associated with poor prognosis a lack response to conventional therapies. Immunotherapies have emerged as promising approach for especially through identification tumor-specific immunogenic epitopes that can trigger targeted immune response. This study aimed identify development specific immunotherapies. Methods: We used high-throughput data screening bioinformatics tools antigens epitope selection. The immunogenicity selected was studied after coculture peripheral blood mononuclear cells obtained from healthy donors or patients plasmacytoid dendritic cell line loaded peptides. Specific CD8 + T amplification functionality were determined by labeling tetramers IFN-γ CD107a expression (flow cytometry ELISpot). Results: analyzed transcriptional gene landscape screen set 16 ectopically expressed genes majority samples. Epitopes predicted bind HLA-A*02:01 high affinity further validated their using previously described ex vivo activation assays patient cells. Three out 30 tested epitopes, namely FLWGPRALV (MAGE-A3), FMNKFIYEI (AFP), KMFHTLDEL (LRRC46), elicited strong T-cell response, assays, degranulation secretion assays. Conclusions: These results highlight potential these peptides be considered targets discovery such should improve immune-based treatments combination current treatment approach.

Language: Английский

Citations

0
Neoantigen vaccines: advancing personalized cancer immunotherapy DOI Creative Commons
Alaa A. A. Aljabali,

Yassmen Hamzat,

Alaa Alqudah

et al.

Exploration of Immunology, Journal Year: 2025, Volume and Issue: 5

Published: April 8, 2025

Neoantigen vaccines are a promising strategy in cancer immunotherapy that leverage tumor-specific mutations to elicit targeted immune responses. Although they have considerable potential, development challenges related antigen prediction accuracy, manufacturing complexity, and scalability remain key obstacles their widespread clinical use. This literature review was conducted using PubMed, Scopus, Web of Science, Google Scholar databases identify relevant studies. Keywords included “neoantigen vaccines,” “personalized immunotherapy,” “tumor heterogeneity,” “bioinformatics pipelines,” “prediction algorithms”. Clinical trial data were sourced from ClinicalTrials.gov, Trialtrove, other publicly available registries. Eligible studies peer-reviewed research articles, systematic reviews, trials focusing on neoantigen vaccine development, bioinformatic strategies, immunotherapy. Tumor heterogeneity clonal evolution significantly impact efficacy, necessitating multi-epitope targeting adaptive design. Current algorithms suffer high false-positive false-negative rates, requiring further integration with multi-omics machine learning enhance accuracy. Manufacturing remains complex, time-intensive, costly, advancements standardization automation. Combination therapies, such as checkpoint inhibitors adoptive cell counteract the immunosuppressive tumor microenvironment, improving treatment outcomes. hold great potential for personalized therapy but require bioinformatics, scalability, immunomodulatory strategies efficacy. Continued interdisciplinary collaboration essential refining applications.

Language: Английский

Citations

0
Immunoinformatics Design of a Multiepitope Vaccine (MEV) Targeting Streptococcus mutans: A Novel Computational Approach DOI Creative Commons
Romen Singh Naorem,

Bandana Devi Pangabam,

Sudipta Sankar Bora

et al.

Pathogens, Journal Year: 2024, Volume and Issue: 13(10), P. 916 - 916

Published: Oct. 21, 2024

Dental caries, a persistent oral health challenge primarily linked to

Language: Английский

Citations

1
Biodegradable nanoplatforms for antigen delivery: part I – state of the art review of polymeric nanoparticles for cancer immunotherapy DOI Creative Commons

E. Vega,

Jordi Madariaga Burgos,

Eliana B. Souto

et al.

Expert Opinion on Drug Delivery, Journal Year: 2024, Volume and Issue: 21(8), P. 1251 - 1262

Published: Aug. 2, 2024

Polymeric nanoparticles used for antigen delivery against infections and cancer immunotherapy are an emerging therapeutic strategy in promoting the development of innovative vaccines. Beyond their capability to create targeted systems with controlled release payloads, biodegradable polymers utilized ability enhance immunogenicity stability antigens.

Language: Английский

Citations

0
Comparative Analysis of IMT-P8 and LDP12 Cell-Penetrating Peptides in Increasing Immunostimulatory Properties of HIV-1 Nef-MPER-V3 Antigen DOI
Seyed Mehdi Sadat,

Shekoufa Jahedian,

Sahar Sabaghzadeh

et al.

Protein and Peptide Letters, Journal Year: 2024, Volume and Issue: 31(10), P. 818 - 826

Published: Nov. 19, 2024

There have been great efforts in vaccine design against HIV-1 since 1981. Various approaches investigated, including optimized delivery systems and effective adjuvants to enhance the efficacy of selective antigen targets. In this study, we evaluated efficiency IMT-P8 LDP12 cell penetrating peptides eliciting immune responses Nef-MPER-V3 fusion protein as an candidate. Moreover, potency HP91 HSP27 was compared adjuvant female BALB/c mice through different regimens. For purpose, recombinant Nef-MPER-V3, IMT-P8-Nef-MPER-V3 LDP-Nef- MPER-V3 proteins were generated on a large scale. After immunization with regimens, secretion antibodies, cytokines granzyme B by ELISA. Our results demonstrated that immunized receiving linked exhibited significantly higher levels IgG other groups. The IMT-P8-Nef- Hp91 group showed highest level humoral response, which stronger than formulation using same (LDP-Nef-MPER-V3). Additionally, combination either or Hsp27 resulted robust induction IFN-γ LDP-Nef-MPER-V3 group. Furthermore, cytotoxic T lymphocyte (CTL) activation proliferation assays indicated served more CPP, particularly when used conjunction adjuvant. Altogether, data formulations responses. This has high induce both immunity arms, specifically incorporated IMT-P8, priority LDP12. greater cellular HSP27. These findings suggest potential superior system for enhancing development.

Language: Английский

Citations

0